Spots Global Cancer Trial Database for Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer
Official Title: Icotinib With Concurrent Radiotherapy Versus Etoposide/Cisplatin With Concurrent Radiotherapy in Stage III Non-small Cell Lung Cancer With EGFR 19/21 Mutation
Study ID: NCT02215356
Conditions
Study Description
Brief Summary: This randomised, multi-center, controlled trial is designed to assess the efficacy and safety of icotinib with concurrent radiotherapy versus chemotherapy with concurrent radiotherapy in non-small cell lung cancer
Detailed Description: This randomised, multi-center, controlled trial is designed to assess the efficacy and safety of icotinib with concurrent radiotherapy versus etoposide/cisplatin with concurrent radiotherapy in stage III non-small cell lung cancer with EGFR 19/21 Mutation, the primary endpoint is progression-free survival
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Chinese Academy of Medical Sciences Cancer Hospital, Beijing, Beijing, China
People's Liberation Army 307 Hospital, Beijing, Beijing, China
Peking University Third Hospital, Beijing, Beijing, China
Beijing Union Medical College Hospital, Beijing, Beijing, China
Dongguan City People's Hospital, Dongguan, Guangdong, China
Sun Yat-sen Cancer Hospital, Guangzhou, Guangdong, China
Nanfang Hospital, Guangzhou, Guangdong, China
Guangxi Zhuang Autonomous Region People's Hospital, Nanning, Guangxi, China
Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, China
First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Tongji Hospital, Wuhan, Hubei, China
Hunan Provincial Tumor Hospital, Changsha, Hunan, China
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
Nantong Tumor Hospital, Nantong, Jiangsu, China
Jiangxi Provincial Cancer Hospital, Nanchang, Jiangxi, China
Tumor Hospital of Jilin Province, Changchun, Jilin, China
Liaoning Provincial Tumor Hospital, Shenyang, Liaoning, China
Shanghai Chest Hospital, Shanghai, Shanghai, China
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Shanxi Tumor Hospital, Taiyuan, Shanxi, China
Sichuan Provincial Tumor Hospital, Chengdu, Sichuan, China
Tianjin Cancer Hospital, Tianjin, Tianjin, China
First Affiliated Hospital of Xinjiang Medical University, Wulumuqi, Xinjiang, China
Tumor Hospital of Yunnan Province, Kunming, Yunnan, China
Hangzhou First People's Hospital, Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Contact Details
Name: Lvhua Wang, MD
Affiliation: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Role: PRINCIPAL_INVESTIGATOR
Name: Xiaolong Fu, MD
Affiliation: Shanghai Chest Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
